The short version: The GLOW peptide blend combines three research peptides in a single vial: GHK-Cu, BPC-157, and TB-500, most often in a 50/10/10 mg ratio totaling 70 mg. Each component has been studied separately in preclinical or clinical settings, but no published study has evaluated the three-peptide combination as a formulation. The blend is sold as a research-use-only laboratory chemical, not a medication. Before ordering, verify the supplier’s lot-specific certificate of analysis, confirm the testing laboratory is independent, and check that the listing maintains a strict research-use-only boundary. Stack Research publishes lot-specific documentation for its GLOW 70 research peptide blend, which is the baseline standard any researcher should expect.
Search for “GLOW peptide blend” and you will find a market that has grown rapidly around a three-peptide stack that combines a copper peptide with two tissue-repair peptides. The individual components have well-documented research histories. The combination, however, has not been studied as a formulation, and many listings blur the line between what the literature supports for each peptide separately and what it claims for the blend as a whole.
This guide is written for laboratory researchers who need to understand what the GLOW blend is, what the published research actually shows for each component, why the combination has not been studied, and what documentation to verify before placing an order.
What the GLOW peptide blend is
The GLOW blend is a fixed-ratio combination of three peptides: GHK-Cu (copper tripeptide-1), BPC-157, and TB-500 (thymosin beta-4 fragment). The most common configuration is a 70 mg total vial containing 50 mg of GHK-Cu, 10 mg of BPC-157, and 10 mg of TB-500. The blend is supplied as a lyophilized powder labeled for laboratory research use only.
The name derives from GHK-Cu’s documented role in collagen synthesis and skin remodeling, which is the component most associated with cosmetic and dermatological research. A physician-authored review of peptide stacks describes the three compounds as addressing different phases of tissue repair: BPC-157 drives angiogenesis, TB-500 promotes cell migration, and GHK-Cu supports matrix remodeling. The review notes that no study has tested the combination of all three peptides together.
That distinction is the most important thing a researcher can understand about the GLOW blend. The individual components have evidence bases of varying strength. The combination does not. A supplier that presents the blend as if its effects are the sum of its parts is making an assumption that has not been tested in any published study.
The individual components: what the research shows
GHK-Cu: copper peptide with the strongest topical evidence
GHK-Cu is a tripeptide composed of glycine, histidine, and lysine, bound to a copper(II) ion. It occurs naturally in human plasma and declines significantly with age. A review published in BioMed Research International in 2015 describes GHK-Cu as a natural modulator of multiple cellular pathways in skin regeneration, stimulating collagen synthesis, promoting angiogenesis, and regulating matrix metalloproteinases.
Among the three components in the GLOW blend, GHK-Cu has the strongest human clinical evidence base, though the evidence is concentrated in topical applications. A 2026 review in Pharmaceutics concluded that the highest biological evidence level for GHK-Cu in photoaging and cosmetic remodeling is B2 to B5, corresponding to small pilot studies. The authors note that injectable GHK-Cu lacks published human trials. A Phase 2 split-wound study of topical GHK-Cu gel for acute skin wound healing was recruiting as of August 2026.
BPC-157: preclinical evidence, no human trials for this indication
BPC-157 is a synthetic pentadecapeptide derived from human gastric juice protein. A review published in Cell and Tissue Research in 2019 examined BPC-157’s role in accelerating musculoskeletal soft tissue healing. The review found that BPC-157 was studied extensively in animal models for tendon, ligament, and muscle repair, but noted that human clinical trial data is lacking.
USADA’s athlete guidance on BPC-157 states plainly that there are no human clinical trials establishing efficacy for any diagnosis or treatment, and that because the compound has not been extensively studied in humans, it is unknown whether there is a safe dose. The FDA previously placed BPC-157 in Category 2 of bulk drug substances that may present significant safety risks when used in compounding; following the April 2026 changes, the agency’s list now shows it among withdrawn nominations pending advisory committee review, which does not authorize its use in compounding.
TB-500: actin regulation and cell migration research
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in actin regulation and cell migration. A review published in Trends in Molecular Medicine in 2005 described thymosin beta-4 as an actin-sequestering protein that is upregulated in response to tissue injury and plays a role in cell migration and tissue repair.
TB-500 is studied in animal models for wound healing, cell migration, and inflammation modulation. Like BPC-157, it lacks published human clinical trials for musculoskeletal indications. The FDA placed TB-500 in Category 2 in 2023, alongside BPC-157. On April 15, 2026, the FDA announced it would remove 12 peptides from Category 2 pending PCAC evaluation and separately removed GHK-Cu from Category 1; the agency’s current list shows BPC-157, TB-500, and GHK-Cu among withdrawn nominations. Legal analysis from Orrick notes that the removal does not constitute authorization for compounding but moves the substances into a regulatory grey zone pending formal review.
Video: A four-week trial of the GLOW stack
This third-person video documents an individual’s experience and is not a clinical study. It is not affiliated with Stack Research and is not a substitute for laboratory documentation or the published literature.
Why the combination has not been studied
The most important limitation of the GLOW blend is also the simplest to state: no published study has evaluated the three-peptide combination as a formulation. This is not a minor caveat. It means that the interaction between the three peptides, their combined stability in a single lyophilized vial, and their combined effects in any biological system are all unknown from a published-evidence perspective.
The Stack Research GLOW 70 product page lists the blend’s composition and lot documentation; it does not present any published research on the three-peptide formulation itself.
Many suppliers present the blend as if its effects are the straightforward sum of its components, which is an assumption that has not been tested. The physician-authored review notes that “no study has tested BPC-157 + TB-500 + GHK-Cu” and that claims about synergy are extrapolations from separate studies, not findings from combined research.
For researchers, the practical implication is that the GLOW blend is a novel formulation in the research sense. Any experiment using it is testing a combination that has not been characterized in the published literature. That does not make the blend unsuitable for research. It means that the research question is about the blend itself, not about a well-characterized combination with a known evidence base.
The researcher’s verification checklist for the GLOW blend
The difference between a defensible purchase and a gamble comes down to documentation. Here is what to check, in order.
1. Lot-specific certificate of analysis for the blend, not just the components
A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. For a blend, this is more complicated than for a single peptide. The COA should confirm the identity and quantity of each component in the blend, not just the total peptide content. A report that lists only “GLOW 70: 65.63 mg measured” without breaking down the individual components is incomplete.
Stack Research publishes a lot-specific report for its GLOW 70 research peptide. The current lot documentation shows identity conforms, HPLC purity of 99.61 percent, and measured content of 65.63 mg. The report identifies the testing laboratory as Accumark Labs and includes a report ID (X7MB-H2H8) that can be cross-referenced. The exact SKU (STK-BBG70) and lot number (1035) are visible on the product page.
2. What a blend COA should test
A certificate for a peptide blend should include identity confirmation for each component, purity by HPLC, measured content, endotoxin, and sterility. For the GLOW blend specifically, the identity confirmation should establish that all three peptides (GHK-Cu, BPC-157, and TB-500) are present and match their reference standards. The copper content should be reported for the GHK-Cu component.
If a supplier’s COA for the GLOW blend reports only a single purity percentage without component-specific identity results, that is a gap. It may not be a dealbreaker for every research context, but it is a data point about how thoroughly the supplier tests its material.
3. The research-use-only boundary
Every legitimate research peptide supplier uses the research-use-only (RUO) designation. The Stack Research testing documentation states that laboratory documentation does not provide dosing, administration, diagnosis, treatment, or human-use guidance. The RUO label means the product is not intended for diagnostic, therapeutic, or human use.
What to watch for is a supplier that uses the RUO label while simultaneously publishing dosing information, before-and-after photos, or customer testimonials about human use. That combination is what the FDA has cited in warning letters. A supplier that maintains the boundary consistently is easier to trust because it is not trying to have it both ways.
4. Pricing and configuration transparency
The GLOW blend is typically sold as a 70 mg vial. The price per milligram of total peptide should be calculable from the listing. If the listing obscures the vial size, bundles it with accessories, or requires a minimum order to see pricing, that is friction that makes comparison harder. Stack Research lists its 70 mg GLOW 70 vial at $149.90 with volume pricing available to verified research accounts. The product page shows the exact SKU and lot information alongside the price.
5. Stability and storage considerations
A three-peptide blend introduces stability questions that a single peptide does not. Each component has its own optimal storage conditions, and the blend’s stability as a combined formulation has not been characterized in published literature. GHK-Cu, for example, is most stable in a neutral to slightly acidic pH range, while BPC-157 and TB-500 may have different stability profiles.
A supplier that provides storage guidance on its product page or research library is offering information that affects the integrity of the material after it ships. The Stack Research peptide storage guide covers handling and storage conditions for lyophilized research peptides.
How Stack Research approaches GLOW blend documentation
Stack Research is a research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s testing page describes the analytical methods used and the laboratories that perform the work. For researchers who need to verify a supplier before ordering, the relevant questions are whether the documentation is specific to the lot, whether the testing laboratory is named, and whether the results can be independently reviewed.
The GLOW 70 product page lists the lot number, testing laboratory, and report ID alongside the price. A supplier that acknowledges the limits of the evidence for a combination product is operating at a different standard than one that implies the blend’s effects are established.
The COA library collects the reports for all products so that researchers can compare documentation across configurations. The company maintains a research-use-only boundary throughout its product descriptions and does not publish dosing or administration guidance.
Comparing GLOW blend documentation standards
The table below outlines the documentation elements that separate a transparent listing from an incomplete one. It is not a ranking of suppliers but a framework for evaluating any listing you encounter.
| Documentation element | What a complete listing shows | Red flag if missing |
|---|---|---|
| Lot-specific COA | Report tied to the exact lot number, with testing lab named | Generic COA or no lot number |
| Component identity | Each peptide in the blend identified separately | Single identity result for the whole blend |
| Purity by HPLC | Reported for the tested sample, with method stated | Purity percentage only, no method |
| Measured content | Actual total peptide mass, not just label claim | No fill or content verification |
| Endotoxin and sterility | Pass/fail results for both | Omitted entirely |
| Research-use-only boundary | No dosing, administration, or human-use content | Testimonials, before/after photos, influencer dosing content |
| Evidence disclosure | States that components are studied separately, not as a blend | Implies combination effects are established |
| Price transparency | Vial size, price, and SKU visible together | Price hidden behind account creation or minimum order |
The table is not a guarantee. A supplier can produce all of these documents and still be selling a product that does not match the report, which is why independent testing services exist. But a supplier that cannot produce the documents at all is not worth the time it takes to evaluate further.
Common questions researchers ask about the GLOW blend
What is the GLOW peptide blend made of?
The GLOW blend combines three peptides in a fixed-ratio vial: GHK-Cu (copper tripeptide-1), BPC-157, and TB-500 (a thymosin beta-4 fragment). The most common configuration is a 70 mg vial containing 50 mg of GHK-Cu, 10 mg of BPC-157, and 10 mg of TB-500. The blend is sold as a research-use-only laboratory chemical.
Has the GLOW blend been studied in clinical trials?
No. No published study has evaluated the three-peptide combination as a formulation. The individual components have separate research histories, with GHK-Cu having the strongest topical human evidence, but the blend itself has not been tested in clinical trials.
What purity should a GLOW blend COA show?
Purity by HPLC above 95 percent is the typical threshold for research-grade peptides. The purity figure is only meaningful alongside identity and content results. For a blend, the identity confirmation should establish that all three peptides are present and match their reference standards. A single purity percentage without component-specific identity results is incomplete.
How do I verify that a GLOW blend COA is real?
Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity. If a supplier cannot tell you which laboratory performed the test, the COA cannot be independently verified.
What is the difference between the GLOW blend and the KLOW blend?
The GLOW blend contains GHK-Cu, BPC-157, and TB-500. The KLOW blend contains KPV in addition to GHK-Cu, BPC-157, and TB-500. The naming reflects the components included. Researchers should confirm the identity of any product by its COA, not by the brand name on the vial.
What should I do if a supplier’s listing makes health claims?
Treat it as a disqualifying signal. Health claims on a research peptide listing are the exact pattern the FDA has cited in warning letters. A supplier that describes what the blend “does” for the body is marketing an unapproved drug, regardless of the research-use label elsewhere on the page.
Important notice: This article is provided for educational and informational purposes only. It does not constitute medical, legal, or regulatory advice. Research peptides discussed here are sold exclusively for laboratory research use and are not approved by the FDA or any other regulatory agency for human or veterinary use. Nothing in this article should be construed as guidance for human consumption, dosing, or administration. Statements regarding dietary supplements and research compounds have not been evaluated by the FDA. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction. Always consult the product label, the certificate of analysis, and a qualified professional before making decisions about any substance.